Skip to content

NIDCR Behavioral Intervention UG3/UH3 Eligibility Guide

Updated 17 official sources

Quick Answer: NIDCR's behavioral and social intervention UG3/UH3 opportunity is PAR-25-188. It funds a 1-year planning phase (UG3) followed by up to 5 years of trial conduct (UH3) for behavioral or biopsychosocial trials tied to dental, oral, or craniofacial (DOC) health.

Full answer and how we checked it

The next new-application due date is February 8, 2027. There's no budget cap, but in past awards the median UH3 year cost $780,941 in total costs.

Who this is for: This guide is for dental, oral, and craniofacial researchers, behavioral scientists, and clinical trial teams at universities, dental schools, and research institutes who want to know whether a behavioral DOC trial fits PAR-25-188 before they spend 6 to 10 weeks drafting.

Data note: This guide uses NIH PAR-25-188 (opens in a new tab), NIH clinical trials policy (opens in a new tab), NIH data management policy (opens in a new tab), Grants.gov listing 357462 (opens in a new tab), USAspending.gov (opens in a new tab) obligations for assistance listing 93.121, and NIH RePORTER award records for NIDCR UG3 and UH3 projects, all checked on October 18, 2026.

In this guide

Quick Facts

Agency
HHS
Deadline
Jan 6, 2028
Status
Open

Assistance Listing 93.121: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.121, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
1,951
Avg Award (whole listing)
$2,735,109
Median Award (whole listing)
$1,097,670
Total Funding (FY2024, whole listing)
$379.1M
YoY Funding Trend
-0.3%

Data last verified: May 19, 2026

According to NIH PAR-25-188 (opens in a new tab), this NOFO supports planning and implementation of behavioral and biopsychosocial intervention studies tied to DOC health, as well as associated medical and mental health conditions. NIH marks the opportunity UG3/UH3 Clinical Trial Required, so the question isn't whether human subjects rules apply. They do.

The narrower question is whether the project is a NIDCR behavioral intervention trial with enough operational proof to survive both study-section review and NIDCR milestone oversight. Strong science can lose time when the team treats UG3/UH3 as a normal R01 with a longer timeline. It isn't. The application needs a working trial engine.

Use this guide with the live NIDCR behavioral intervention UG3/UH3 program page, NHLBI clinical trial pilot guide, NCATS CTSA SIP RC2 guide, NIH emergency revision guide, what is a NOFO, and the Grantsights grant database.

October 2026 Source Check

February 8, 2027 is the next new-application due date for PAR-25-188. Grantsights checked the NOFO's key-dates table against the calendar on October 18, 2026. The June 8, 2026 and October 8, 2026 new-application dates have passed. Remaining new dates are February 8, 2027, June 8, 2027, and October 8, 2027. Remaining resubmission dates are November 9, 2026, March 8, 2027, July 7, 2027, and November 8, 2027. All applications are due by 5 p.m. local time of the applicant organization, and the NOFO expires January 7, 2028.

Only new and resubmission applications are allowed. A team that wants to extend an ongoing NIDCR trial uses PAR-25-062 (opens in a new tab), NIDCR's renewal and revision route for clinical trials, not this one. PAR-25-188 reissued PAR-21-317 (opens in a new tab), and NIH added a March 31, 2025 note saying the NOFO "was updated to align with agency priorities," so reread the current text even if you applied under an older version.

Source checkWhat PAR-25-188 says
Due datesNew: Feb 8, Jun 8, Oct 8, 2027. Resubmission: Nov 9, 2026; Mar 8, Jul 7, Nov 8, 2027
Review cycle for Feb 8, 2027Merit review July 2027, council October 2027, earliest start December 2027
UG3 phaseMaximum 1 year of planning
UH3 phaseMaximum 5 years of trial conduct
BudgetNot limited; $500,000+ direct in any year needs NIDCR contact 8 weeks ahead
Clinical trialRequired, with at least one NIH-defined trial in the UH3 phase
ExcludedFDA-regulated drug, device, or biologic tests (use PAR-25-057)
Pre-application contactStrongly encouraged, early in planning

The fastest fail signal is an application that has a persuasive behavioral idea but can't show site-level accrual, measurable milestones, and a clinical-trial monitoring path.

7 NIDCR Behavioral Social Intervention UG3 UH3 Eligibility Checks

7 stop checks decide whether drafting is worth starting. If 2 fail, pause the submission and fix them first.

Stop checkStrong signalRed flag
DOC fitDental, oral, or craniofacial outcome is centralDOC health is a side outcome
Intervention typeBehavioral or biopsychosocial mechanism is clearDrug, biologic, or device test dominates
Trial statusNIH clinical trial definition is metTeam tries to frame a trial as non-trial
UG3 logic12 months of concrete planning outputsUG3 is a full pilot of the UH3 intervention
UH3 logicImplementation phase can open and finishTrial engine is still vague
MilestonesAnnual milestones are objective and measurableMilestones are narrative promises
Accrual proofSite-level recruitment and retention proof existsStudy Accrual and Retention Plan is optimistic but thin

According to NIH, applications without a Study Timeline and Milestone Plan are incomplete and won't be reviewed. That isn't a writing detail. It's a gate. The NOFO lists 4 more non-responsive triggers: no overall goals and hypotheses with aims for each phase, no NIH-defined trial in the UH3 phase, no hypothesized mechanism of causal change (or a strong argument why one doesn't apply), and any test of an FDA-regulated product.

One rule catches teams that plan to use the UG3 as a dress rehearsal. The NOFO says "a full pilot of the UH3 planned intervention is prohibited in the UG3 planning phase." Acceptability and feasibility work on parts of the intervention is fine; a scaled-down version of the whole trial isn't.

Grantsights Analysis of 18 NIDCR Behavioral UG3/UH3 Awards

18 projects have been funded under PAR-25-188 and the 3 notices it descends from (PAR-18-656, PAR-21-197, and PAR-21-317), for $56.9 million in total costs from FY2019 through FY2026. Grantsights analysis of NIH RePORTER (opens in a new tab) records produced that count and the figures below. Method: we pulled every NIDCR UG3 and UH3 record from the RePORTER API on October 18, 2026 (255 records), kept projects whose UG3 or UH3 record cited one of those 4 notices, and matched each UG3 to its UH3 by NIDCR serial number, because the core project number changes prefix (UG3DE028866 becomes UH3DE028866) at transition.

MeasureResult
Projects funded, FY2019 to FY202618, in 12 states plus DC
UG3s started FY2019 to FY2024 that later received UH3 funding16 of 16
Projects still in the UG3 phase, October 20262 (Vanderbilt, UTHealth Houston)
Median UG3 fiscal-year total cost$334,473 (31 fiscal-year records)
Median UH3 fiscal-year total cost$780,941 (54 records; range $526,834 to $1,287,696)
UH3 years with $500,000+ in RePORTER's direct-cost field47 of 54
Median months from UG3 start to first UH3 budget period24.0 (range 12.0 to 43.8)
Funded on a resubmission (A1)2 of 18

Read the transition rate carefully. RePORTER shows funded projects only, so 16 of 16 says that a UG3, once awarded, has reliably moved to UH3 in this program. It says nothing about how many applications were funded in the first place. The NOFO itself warns that "the UG3 award does not guarantee subsequent UH3 funding," and the transition rests on an NIDCR administrative review and available funds.

The 24-month median comes from older rules. 12 of the 16 projects that reached UH3 had 2 UG3 fiscal years, which the predecessor notices allowed. PAR-25-188 cuts the UG3 to 1 year, so the planning work that past teams spread over 2 budget periods now has to fit in 12 months.

Specific awards show the range. For example, Boston University received $493,873 for a 2019 UG3 testing a smoking cessation induction intervention delivered through a virtual reality headset during a dental cleaning, and its UH3 began 12 months later (opens in a new tab) at $824,998 for the first year. The University of Texas Health Science Center at Houston moved CATCH Healthy Smiles, a cluster-randomized trial of an elementary school oral health program, from a $460,148 UG3 in FY2020 to a UH3 of $1,108,164 (opens in a new tab) in FY2021. At the slow end, the University of Texas Rio Grande Valley's one-session treatment for dental phobia held UG3 funding in FY2022 and FY2023 and received its first UH3 award in FY2026, about 44 months after the UG3 began.

The first award under PAR-25-188 itself went to UTHealth Houston in FY2026: "SmartMouth: Nudging Dentists Towards Evidence-based Pain Management," a 1-year UG3 of $821,788 in total costs running September 7, 2026 to August 31, 2027. It was funded on resubmission (A1), as was HealthPartners Institute's 2023 UG3 in Minnesota, which tests a provider-directed intervention for HPV vaccine promotion in dental settings. A scored-but-unfunded first submission isn't the end of the road here.

5 Source Facts Applicants Should Know

5 source facts belong in the decision memo before anyone drafts aims. First, according to NIH, PAR-25-188 uses a biphasic UG3/UH3 cooperative agreement submitted as one application, and reviewers give it a single overall impact score, so a weak UH3 plan drags down a strong UG3 plan.

Second, according to USAspending.gov (opens in a new tab) data, assistance listing 93.121 (Oral Diseases and Disorders Research, NIDCR's listing) had $379.1 million in grant obligations in FY2024 and $378.9 million in FY2025. That figure covers all of NIDCR's grants, not this NOFO, but it shows the institute's spending was flat across those 2 years.

FactSource-backed read
NOFOPAR-25-188, reissue of PAR-21-317
AgencyNIDCR, NIH
MechanismUG3/UH3 cooperative agreement
Clinical trial statusClinical Trial Required
Eligible applicantsU.S. universities, nonprofits, for-profits, governments, tribes; no foreign organizations
Live listingGrants.gov listing 357462

Third, review isn't done by a standing CSR study section. The NOFO says applications go to a Scientific Review Group convened by NIDCR, then to an NIH advisory council for second-level review. Fourth, the NOFO says the UH3 section should cover subjects, recruitment, design, methods, assessment, measures, statistical plan, safety, and confidentiality. Fifth, NIH staff are substantially involved: an NIDCR Project Scientist consults on UG3 and UH3 milestones, joins progress calls, and reviews enrollment against targets.

2026 NIH-Wide Rules That Change This Application

6 NIH-wide changes from 2025 and 2026 apply to a PAR-25-188 submission, and none of them appear in the NOFO's own text.

ChangeWhat it means for a UG3/UH3 teamSource
Simplified review frameworkFactor 1 (Importance) and Factor 2 (Rigor and Feasibility) are scored 1 to 9; Factor 3 (Expertise and Resources) is rated appropriate or notNOT-OD-24-010 (opens in a new tab)
Unified Funding StrategyInstitutes "will not rely on funding paylines" from the January 2026 council roundNIH Extramural Nexus (opens in a new tab)
Common FormsBiosketch and Current and Pending (Other) Support must be the SciENcv Common Forms; errors block submission since May 8, 2026NOT-OD-26-018 (opens in a new tab), NOT-OD-26-079 (opens in a new tab)
Six-application limitNo more than 6 new, renewal, resubmission, or revision applications per PI per calendar yearNOT-OD-25-132 (opens in a new tab)
15% indirect cost capNot in effect; budget with your negotiated rateNOT-OD-26-060 (opens in a new tab)
Continuing resolutionNIH runs at the FY2026 level through December 11, 2026NOT-OD-26-131 (opens in a new tab)

According to NOT-OD-24-010, the Study Timeline that clinical trial applications must include is now judged inside Factor 2, as part of scientific merit, rather than as a separate compliance item. For a UG3/UH3, that puts the milestone plan in front of the scored criteria. PAR-25-188's review section repeats this: for clinical trial applications, reviewers "evaluate whether the study timeline and milestones are feasible."

The Unified Funding Strategy matters because NIDCR can now fund out of score order more openly. The November 2025 announcement says institutes will weigh peer review "in its entirety" alongside priorities, career stage, and the funding an investigator already holds. A UG3/UH3 with a mid-range score and a clear NIDCR priority fit isn't automatically out.

On indirect costs, NIH's February 2025 notice setting a 15% rate (NOT-OD-25-068) is still posted, but courts blocked it, and the First Circuit affirmed that ruling on January 5, 2026. Section 224 of the FY2026 appropriations act, quoted in NOT-OD-26-060, requires NIH to apply indirect cost rules as they stood in the third quarter of FY2017, and NOT-OD-26-131 keeps FY2026 mandates in force under the CR. The indirect cost rate guide covers the calculation.

Two practical consequences: every senior or key person needs SciENcv Common Forms ready well before the due date (see the NIH biosketch guide), and a PI who already plans R01 or R21 submissions this year should count this application toward the six. The NIH grants guide covers both rules for other mechanisms.

What NIH Doesn't Tell You

4 practical questions sit outside the NOFO, and NIH won't answer them for you. First, the application must prove the DOC link without sounding like a generic behavior-change study. The funded list helps here: a speech telepractice trial for children with repaired cleft palate (Texas Tech), a sensory-adapted dental environment for children with and without dental fear and anxiety (USC), and a no-show prevention trial in dental clinics serving underserved patients (Wisconsin) all put a DOC outcome at the center. A broad wellness program with a dental subscale would tell a weaker story.

Second, the UG3 phase can't be a place to discover the whole trial, and under PAR-25-188 it's only 12 months. Treat the UG3 as a final assembly phase: protocol, manual of procedures, measurement reliability, recruitment proof, data systems, and regulatory setup. The NOFO points to NIDCR templates for these documents.

Third, cooperative agreement terms matter. NIDCR says milestones "will be refined and finalized in consultation with NIDCR staff," and if a project misses annual milestones, NIDCR "will consider ending support and negotiating an orderly close-out." NIDCR also appoints any oversight committee members after consulting you, and the NOFO says not to name board members in the application. If your team doesn't want that relationship, this route will feel too managed.

Fourth, the budget almost always triggers an extra step. In the award data above, 47 of 54 UH3 years showed $500,000 or more in RePORTER's direct-cost field, and the PAR-25-188 UG3 funded in FY2026 listed $640,687 in direct costs for its single year. The NOFO says any request of $500,000 or more in direct costs in a year requires contacting a scientific contact at least 8 weeks before submission. A common mistake is treating that as optional pre-application advice. For a February 8, 2027 submission, the 8-week mark falls in mid-December 2026.

If a research team can't name site-level recruitment evidence, milestone triggers, and the clinical-trial monitoring path, skip this route for now and choose a better one before 6 weeks of drafting disappear.

6 Evidence Assets That Make This Trial Stronger

6 evidence assets carry most of the weight with reviewers. Asset 1 is the DOC relevance memo. State the dental, oral, or craniofacial health outcome in 2 direct sentences.

Asset 2 is the causal-mechanism memo. NIH asks for a hypothesized mechanism of causal change or a compelling reason why that isn't applicable, and leaving it out makes the application non-responsive. Don't bury this in background.

Asset 3 is the UG3 deliverable table. List protocol, manual of procedures, recruitment scripts, measure validation, sample size and power work, fidelity monitoring, data management system, regulatory materials, and site activation tasks. The NOFO names each of these as acceptable UG3 aims.

Asset 4 is the UH3 milestone table. According to NIH, UH3 milestones must include regulatory approvals and site activation, ClinicalTrials.gov registration, first subject enrollment, accrual and retention targets, data collection, primary analyses, and the final study report.

Asset 5 is the Study Accrual and Retention Plan, and the NOFO requires that exact filename. NIH says it must show that each recruiting center has access to enough participants who meet the eligibility criteria, with information for every site in a multi-site trial. For example, a hypothetical team with 3 clinics and pre-study eligibility counts by month would be in a better position than a multi-site team with no site-level counts.

Asset 6 is the monitoring and data memo. Link the data and safety monitoring plan, protocol complexity, participant risk, adverse-event process, and the handling of missing data, which the NOFO asks for in the statistical section. Every application also needs a Data Management and Sharing Plan; the data management plan guide covers what NIH expects.

5 Route Choices Before Drafting

5 routes deserve a side-by-side look so the team doesn't force the wrong mechanism.

RouteBetter first read when...Why
PAR-25-188 UG3/UH3Behavioral DOC clinical trial needs planning plus executionNIDCR behavioral trial route fits
PAR-25-057 UG3/UH3Drug, biologic, device, or procedure is the interventionPAR-25-188 excludes FDA-regulated products
PAR-25-062An NIDCR trial is already running and needs more time or scopeRenewals and revisions aren't allowed under PAR-25-188
R34 planningTrial planning is needed but full UH3 execution is prematureSmaller planning route may fit
R01Trial isn't the core product or isn't phasedStandard research route may fit

R34 planning grants work differently at each institute; the NEI R34 planning guide shows one version, and the R01, R21, R03, and K comparison covers the standard mechanisms. For NIDCR's other cooperative agreements, see the NIDCR CEED hub U01 guide.

Warning: don't use PAR-25-188 because it sounds larger. Use it because the trial is ready for a phased cooperative agreement.

6 Bad-Fit Signals

6 bad-fit signals should stop a draft. First, the project is mainly a drug, device, or biologic test. Second, the DOC outcome isn't central. Third, the trial can't meet NIH clinical-trial documentation.

Fourth, the UG3 is being used to decide what the intervention is, or to run a full pilot of it, which the NOFO prohibits. Fifth, recruitment and retention are assumed rather than evidenced. Sixth, the team has no working plan for NIDCR program involvement and milestone oversight.

Some trial concepts have good science but the wrong route. The pattern is easy to spot: the application asks reviewers to believe the trial will become operational after award, but the NOFO asks for proof that it can. That red flag shows up directly in Factor 2 under the simplified framework, because feasibility of the timeline and milestones is now scored there.

21-Day NIDCR UG3/UH3 Readiness Plan

21 days is enough to decide whether to commit, if the work is front-loaded. Days 1 through 3 should confirm DOC fit, intervention type, trial status, applicant eligibility, deadline timing, and whether any year will reach $500,000 in direct costs. If it will, book the NIDCR scientific contact call now, since the 8-week clock runs from the submission date.

Days 4 through 7 should produce the DOC relevance memo, causal mechanism, and route comparison. Days 8 through 12 should write the UG3 deliverables for a 12-month window and the UH3 milestone table. Days 13 through 16 should build the Study Accrual and Retention Plan and safety monitoring logic. Days 17 through 21 should check the human subjects form, trial registration path, data plan, SciENcv Common Forms for every key person, and the PI's count against the six-application limit.

Don't wait until week 5 to ask whether the project fits PAR-25-188. By then the team has usually written too much around the wrong premise.

5 Readiness Signals Before Drafting

5 public signals tell you whether the team is ready to commit. Signal 1 is DOC fit: the dental, oral, or craniofacial outcome is central, the way it is in each of the 18 funded projects listed in RePORTER.

Signal 2 is trial fit: this is Clinical Trial Required, so human-subjects, protocol, registration, safety, monitoring, and data systems must be real.

Signal 3 is milestone fit: the Study Timeline and Milestone Plan is complete enough to pass the completeness screen and specific enough to score well under Factor 2.

Signal 4 is accrual fit: the Study Accrual and Retention Plan includes site-level access and retention proof, not only enthusiasm.

Signal 5 is program-staff contact: PAR-25-188 says applicants are "strongly encouraged" to consult NIDCR staff early. The scientific contact listed in the NOFO is Jill Mattia, Ph.D., Director of NIDCR's Assessment, Technology, and Treatment Outcomes Research Program.

6 Final Research Checks Before Submission

6 final checks close out the draft. Check 1 is NIH PAR-25-188 (opens in a new tab), reread for any notice added after March 2025. Check 2 is NIH clinical trials policy (opens in a new tab). Check 3 is NIH data management policy (opens in a new tab). Check 4 is the Grants.gov listing. Check 5 is site-level accrual evidence. Check 6 is the 8-week NIDCR contact, if any year reaches $500,000 in direct costs.

A useful test: write the DOC outcome, causal mechanism, 12-month UG3 outputs, UH3 milestones, per-site accrual numbers, and monitoring plan as 6 sentences on one page. Any sentence that needs hedging marks the part of the application to fix first.

5 Facts To Confirm Before You Draft

5 facts summarize the opportunity. PAR-25-188 funds behavioral and biopsychosocial DOC clinical trials. It's Clinical Trial Required. The UG3 supports planning for up to 1 year, half the 2 years older versions allowed. The UH3 supports up to 5 years of trial conduct. Applications lacking the Study Timeline and Milestone Plan aren't reviewed.

If your team can't answer those 5 items for its own study, it isn't ready to draft. If it can, search the Grantsights grant database for NIDCR's other open notices before choosing a due date.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 1,951 Assistance Listing records | Avg: $2.7M

REAL DATA
1

Fred Hutchinson Cancer Center

WA

$429.4M
2

President and Fellows of Harvard College

MA

$88.3M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-188 fund?

It funds planning and implementation of NIDCR behavioral and biopsychosocial clinical trials tied to dental, oral, and craniofacial health, including associated medical and mental health comorbidities. It doesn't fund tests of FDA-regulated drugs, devices, or biologics; those go to PAR-25-057.

Is PAR-25-188 a clinical trial NOFO?

Yes. NIH marks it UG3/UH3 Clinical Trial Required, and an application without at least one NIH-defined clinical trial in the UH3 phase is non-responsive and won't be reviewed.

How long do the UG3 and UH3 phases run?

The UG3 planning phase is capped at 1 year and the UH3 trial phase at 5 years. The predecessor notices (PAR-18-656, PAR-21-197, and PAR-21-317) allowed a UG3 of up to 2 years, so older award timelines overstate how long planning can take now.

When is the next PAR-25-188 due date?

As of October 18, 2026, the next resubmission date is November 9, 2026 and the next new-application date is February 8, 2027. Applications are due by 5 p.m. local time, and the NOFO expires January 7, 2028.

Is there a budget cap?

No. The NOFO says budgets aren't limited but must reflect actual need. If any year requests $500,000 or more in direct costs, you must contact the NIDCR scientific contact at least 8 weeks before submitting.

How often do NIDCR behavioral UG3 awards move to the UH3 phase?

Grantsights analysis of NIH RePORTER records found 18 projects funded under this NOFO family since FY2019. All 16 that started their UG3 in FY2019 through FY2024 later received UH3 funding; the other 2 were still in the UG3 phase in October 2026. RePORTER only shows funded projects, so this isn't an application success rate.

What attachment can stop review?

NIH says applications lacking the Study Timeline and Milestone Plan are incomplete and will not be reviewed. Missing overall hypotheses, phase-specific aims, or a causal-change mechanism discussion also makes an application non-responsive.

Who should skip PAR-25-188?

Skip it when the study tests an FDA-regulated drug, device, or biologic, when a renewal of an ongoing NIDCR trial is the goal (that's PAR-25-062), or when recruitment, retention, milestones, and monitoring aren't ready.

Last updated October 18, 2026. Corrected October 18, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.